| Theme |
Liver and Immunology 2019 |
| Title |
Therapeutic Vaccine for Chronic Hepatitis B |
| Author |
Osamu Yoshida |
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine |
| Author |
Yoichi Hiasa |
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine |
| [ Summary ] |
Breaking immune tolerance against HBV is the key to achieving the ideal treatment goal, of "HBsAg seroconversion". Immune therapy, especially vaccine therapy, is a candidate for achieving HBsAg seroconversion. Many different kinds of therapeutic vaccines have been developed by modifying antigens, adjuvant and combination with drugs. Further, several clinical trials of therapeutic vaccine are ongoing throughout the world. NASVAC is one of therapeutic vaccine which contains both HBsAg and HBcAg. NASVAC is adjuvant free and able to be injected through nose. The Phase III clinical trial of NASVAC for treatment of naïve chronic hepatitis B patients was conducted in Bangladesh. NASVAC showed superior anti‒HBV effects and safety compared with peg‒IFN. NASVAC is a promising immune therapy against HBV infection. New clinical trial of NASVAC with modified protocol is in progress at Ehime University. |